Lacerta Bio is a business development consultancy specializing in identifying, assessing, negotiating, and closing licensing and partnership opportunities for the pharmaceutical, biotechnology, and drug delivery industries.
We also work with and support internal business development teams with market research, competitive intelligence, financial modeling, and other support services.
If you need assistance finding or assessing business development and/or partnership opportunities, contact us at email@example.com.
Would You Like To Expand Your Business Into China? Or Perhaps You Seek An Investor or Development Partner? Through our relationship with Ventac Partners, we can help you navigate this rapidly growing, but complex market. Indeed, China is a large and growing opportunity for Western life science companies, as: Life Science in China is BoomingRead More»
Lacerta Bio is seeking parenteral products for in-licensing on behalf of a US-based client. Key criteria are: Products which can be developed via the 505(b)(2) regulatory process in the US No specific therapeutic area Injectable could be infusion, prefilled syringe, or related presentation Products already approved outside the US are especially welcome Delivery / formulationRead More»
Lacerta Bio is looking to transact a business acquisition opportunity in the injectables manufacturing sector. We are seeking manufacturing facilities which have the following criteria: Based outside the US (Europe, Canada, LatAm, Australia, New Zealand preferred) FDA or EU approved manufacturing of parenteral products Could be a stand-alone company which manufactures its own products, or the divestmentRead More»
Few of us will soon forget waking up in Cologne to the news that we will soon have a “President Trump” in the Oval Office in a few months.
So, what will a Trump Administration mean for our industry?
The short answer is “Who knows?”
For better or for worse, we Americans have elected not only a complete political novice, but an individual who clearly does not play by the understood and established rules and norms of diplomacy, behavior, and tact.
Additionally, politicians generally say whatever it takes to get elected. So campaign statements and promises are not worth the electrons spent in communicating them.
Therefore, we as an industry are in a “watch and wait” mode until his Cabinet selections and plans moving forward become a bit clearer.
In fact, nothing is clear at this point. Predicting where our industry will go in the next four years, to the extent it is impacted by this Administration, remains a very open and uncertain question. Caveat emptor.
However, there are a few items we can start thinking about, just based on the election process as a whole:
Coming at a time when companies were making headlines over drug prices, our cause was not being helped by CEOs testifying before Congress.
Therefore, a Trump administration will likely not be too bothered with companies setting prices which they feel are appropriate, and which are negotiated with the payers.
Lower Corporate Taxes – Statements made during the campaign suggest that the next administration will aim to lower corporate tax rates, . This is good for all US-based corporations, including US-based pharma and biotech companies.
If lower taxes mean more jobs in the US, so much the better.
Pro-Business, Not Pro-Freedom – A Trump Administration will pursue pro-business policies, provided they create American jobs. However, statements about taxing companies who leave the US are troubling.
What a company does with their tax savings is their businesses. But let us assume that tax savings are invested in R&D, or distributed to shareholders. Do we want an administration creating a policy which discourages companies from doing what they feel is in their best interests with their profits?
And what is an American pharmaceutical company these days. Pfizer may have started in Brooklyn, but are they still an “American” company? Is Merck? BMS?
Our concern is that any bill introduced in the legislature which curtails corporate freedom will result in a wave of reincorporations, reverse mergers, and other events which could shrink and reshape the US pharmaceutical industry forever.
Only the bankers and the lawyers will be the winners under that scenario.
But, the impact of Obamacare on overall costs remains largely unknown.
Attitude Towards Science – The absurdities regarding President Elect Trump’s statements on global warming lead us to concerns about this Administration’s views on science in general. Will NIH funding suffer?
We would not think so, given that NIH results in the creation of thousands upon thousands of jobs in both academia and industry, not to mention the font of innovation for entire industries.
Conclusion – We have no idea what will happen. And this fact is perhaps what is so troubling. We have elected a President who is simultaneously pro-business and against business freedom and choice.
He wants to grow the US economy by keeping jobs in the US, and by lowering corporate taxes. Yet, we do not know if a replacement for the Affordable Care Act will be increase access to prescription medications or not.
He wants to reduce corporate taxes and simultaneously force companies to stay by imposing a “So Long America” tax. Will companies want to come over to the US if leaving becomes difficult?
Lastly, he has made statements to the effect that he will appoint the “best and brightest” to join his administration and “Make America Great Again.”
While this sounds laudable, whether or not this incoming Administration will be a net positive for our industry remains deeply unknown.
BIO Europe was, yet again, an excellent conference for Lacerta Bio. Having the US election on television screens in the Exhibition Hall made for some surreal moments and discussions. Not a single meeting on Wednesday went without some discussion about the election results. As Americans, we perhaps we do not appreciate how important our elections are
Can we ESKAPE the problem which may kill thousands of human beings over the next decades? First, what is ESKAPE? Initially coined by Dr. Louis Rice, ESKAPE is a handy acronym for six of the most common antibiotic-resistant pathogens. These are: Enterococcus faecium Staphlococcus aureus Klebsiella pneumoniae Acinetobacter baumanni Pseudomonas aeruginosa Enterbacter sp. As Rice puts it,
A few weeks ago, we attended the first annual Commercializing Biotech Innovation Conference in Syracuse, New York. The conference was held in the very new Central New York Biotech Accelerator in Syracuse (which is an outstanding facility, by the way). A central theme of the conference (and a subject which was raised several times during the panel discussions) was